DK1167537T3 - Fremgangsmåde til fremstilling af et monoklonalt antistof - Google Patents
Fremgangsmåde til fremstilling af et monoklonalt antistofInfo
- Publication number
- DK1167537T3 DK1167537T3 DK00912975T DK00912975T DK1167537T3 DK 1167537 T3 DK1167537 T3 DK 1167537T3 DK 00912975 T DK00912975 T DK 00912975T DK 00912975 T DK00912975 T DK 00912975T DK 1167537 T3 DK1167537 T3 DK 1167537T3
- Authority
- DK
- Denmark
- Prior art keywords
- monoclonal antibody
- producing
- hybridoma
- immortalized
- cell
- Prior art date
Links
- 210000004408 hybridoma Anatomy 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 abstract 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8792999 | 1999-03-30 | ||
| PCT/JP2000/002022 WO2000058499A1 (fr) | 1999-03-30 | 2000-03-30 | Procede pour la production d'anticorps monoclonal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1167537T3 true DK1167537T3 (da) | 2008-11-10 |
Family
ID=13928616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK00912975T DK1167537T3 (da) | 1999-03-30 | 2000-03-30 | Fremgangsmåde til fremstilling af et monoklonalt antistof |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8236530B2 (ja) |
| EP (1) | EP1167537B1 (ja) |
| AT (1) | ATE402267T1 (ja) |
| AU (1) | AU754808B2 (ja) |
| CA (1) | CA2368734C (ja) |
| DE (1) | DE60039596D1 (ja) |
| DK (1) | DK1167537T3 (ja) |
| WO (1) | WO2000058499A1 (ja) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7067144B2 (en) | 1998-10-20 | 2006-06-27 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
| US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US7718644B2 (en) * | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
| US7879840B2 (en) * | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US20040229781A1 (en) * | 2000-05-10 | 2004-11-18 | Marks Andrew Robert | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias |
| US7393652B2 (en) * | 2000-05-10 | 2008-07-01 | The Trustees Of Columbia University In The City Of New York | Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) |
| US6489125B1 (en) * | 2000-05-10 | 2002-12-03 | The Trustees Of Columbia University In The City Of New York | Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor |
| US20060293266A1 (en) * | 2000-05-10 | 2006-12-28 | The Trustees Of Columbia | Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure |
| US20040048780A1 (en) * | 2000-05-10 | 2004-03-11 | The Trustees Of Columbia University In The City Of New York | Method for treating and preventing cardiac arrhythmia |
| RS20110024A (sr) | 2001-04-26 | 2011-08-31 | Biogen Idec Ma Inc. | Antitela koja blokiraju cripto i njihova upotreba |
| US7544678B2 (en) * | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
| WO2004080283A2 (en) | 2003-03-07 | 2004-09-23 | The Trustees Of Columbia University, In The City Of New York | Type 1 ryanodine receptor-based methods |
| US8710045B2 (en) * | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
| DK1866339T3 (da) | 2005-03-25 | 2013-09-02 | Gitr Inc | GTR-bindende molekyler og anvendelser heraf |
| US7704990B2 (en) * | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| KR101603632B1 (ko) | 2006-09-10 | 2016-03-16 | 글리코토페 게엠베하 | 항체 발현을 위한 골수성 백혈병 기원의 인간 세포의 용도 |
| ZA200901912B (en) * | 2006-09-10 | 2010-06-30 | Glycotope Gmbh | Use of human cells of myeloid leukaemia origin for expression of antibodies |
| AU2013203482B2 (en) * | 2006-09-10 | 2015-08-27 | Glycotope Gmbh | Fully human high yield production system for improved antibodies and proteins |
| EP1911766A1 (en) * | 2006-10-13 | 2008-04-16 | Glycotope Gmbh | Use of human cells of myeloid leukaemia origin for expression of antibodies |
| WO2008042436A2 (en) | 2006-10-03 | 2008-04-10 | Biogen Idec Ma Inc. | Biomarkers and assays for the treatment of cancer |
| PL1920781T3 (pl) | 2006-11-10 | 2015-06-30 | Glycotope Gmbh | Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów |
| JP2010518115A (ja) | 2007-02-09 | 2010-05-27 | ジェネンテック， インコーポレイテッド | 抗Ｒｏｂｏ４抗体およびそれらのための使用 |
| WO2008112193A1 (en) | 2007-03-12 | 2008-09-18 | Dana-Farber Cancer Institute | Prognostic, diagnostic, and cancer therapeutic uses of fanci and fanci modulating agents |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| TWI580694B (zh) | 2007-11-30 | 2017-05-01 | 建南德克公司 | 抗-ｖｅｇｆ抗體 |
| CA2764377C (en) | 2009-06-10 | 2018-03-27 | Stephen Sanig Research Institute Ltd. | Methods of generating cells exhibiting phenotypic plasticity |
| TW201106972A (en) | 2009-07-27 | 2011-03-01 | Genentech Inc | Combination treatments |
| CA2772715C (en) | 2009-09-02 | 2019-03-26 | Genentech, Inc. | Mutant smoothened and methods of using the same |
| WO2011071577A1 (en) | 2009-12-11 | 2011-06-16 | Genentech, Inc. | Anti-vegf-c antibodies and methods using same |
| CN102770158B (zh) | 2009-12-21 | 2016-10-19 | 霍夫曼-拉罗奇有限公司 | 抗体配制剂 |
| CA2813738A1 (en) | 2010-10-05 | 2012-04-12 | Genentech, Inc. | Mutant smoothened and methods of using the same |
| RU2014110953A (ru) | 2011-08-22 | 2015-09-27 | Гликотоп Гмбх | Микроорганизмы, несущие опухолевый антиген |
| EP2968553B1 (en) | 2013-03-13 | 2020-08-12 | F.Hoffmann-La Roche Ag | Antibody formulations |
| US10653779B2 (en) | 2013-03-13 | 2020-05-19 | Genentech, Inc. | Formulations with reduced oxidation |
| US20140314778A1 (en) | 2013-03-13 | 2014-10-23 | Genentech, Inc. | Formulations with reduced oxidation |
| PL2968466T3 (pl) | 2013-03-13 | 2018-11-30 | F.Hoffmann-La Roche Ag | Preparaty o zmniejszonym utlenianiu |
| HUE049707T2 (hu) | 2013-03-13 | 2020-11-30 | Hoffmann La Roche | Csökkent oxidációjú kiszerelések |
| CA2903589A1 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Cell culture media and methods of antibody production |
| KR20210037745A (ko) | 2013-03-15 | 2021-04-06 | 제넨테크, 인크. | 항산화제를 함유하는 세포 배양 조성물 및 폴리펩티드 생산 방법 |
| PT3049441T (pt) | 2013-09-27 | 2020-01-21 | Hoffmann La Roche | Formulações de anticorpos anti-pdl1 |
| US20150190506A1 (en) | 2013-12-17 | 2015-07-09 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| EP3083690A1 (en) | 2013-12-17 | 2016-10-26 | F.Hoffmann-La Roche Ag | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
| EP3647324A1 (en) | 2013-12-17 | 2020-05-06 | F. Hoffmann-La Roche AG | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
| DK3102197T3 (en) | 2014-02-04 | 2018-11-19 | Genentech Inc | Smoothened mutant and methods for its use |
| AU2015241038A1 (en) | 2014-03-31 | 2016-10-13 | Genentech, Inc. | Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists |
| EP3193932B1 (en) | 2014-09-15 | 2023-04-26 | F. Hoffmann-La Roche AG | Antibody formulations |
| KR20170096112A (ko) | 2014-11-17 | 2017-08-23 | 제넨테크, 인크. | Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법 |
| AU2016215227A1 (en) | 2015-02-04 | 2017-09-21 | Assistance Publique-Hopitaux De Paris | Mutant smoothened and methods of using the same |
| JP6896650B2 (ja) | 2015-06-17 | 2021-06-30 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用した局所進行性または転移性乳癌の治療方法 |
| TW202440903A (zh) | 2015-08-04 | 2024-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法（一） |
| SG11201804951SA (en) | 2015-12-30 | 2018-07-30 | Genentech Inc | Use of tryptophan derivatives for protein formulations |
| IL299759A (en) | 2015-12-30 | 2023-03-01 | Genentech Inc | Formulations with reduced polysorbate dissolution |
| CN108368179B (zh) | 2016-01-08 | 2022-08-23 | 豪夫迈·罗氏有限公司 | 使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法 |
| EP3411396A1 (en) | 2016-02-04 | 2018-12-12 | Curis, Inc. | Mutant smoothened and methods of using the same |
| MX2018010546A (es) | 2016-03-15 | 2019-02-20 | Chugai Pharmaceutical Co Ltd | Metodos de tratamiento de cancer que usan antagonistas de union al eje de muerte programada 1 (pd-1) y anticuerpos anti glipicano 3 (gpc3). |
| WO2018029124A1 (en) | 2016-08-08 | 2018-02-15 | F. Hoffmann-La Roche Ag | Therapeutic and diagnostic methods for cancer |
| WO2019219889A1 (en) | 2018-05-18 | 2019-11-21 | Glycotope Gmbh | Anti-muc1 antibody |
| MY205645A (en) | 2018-06-23 | 2024-11-02 | Genentech Inc | Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor |
| TW202011991A (zh) | 2018-07-18 | 2020-04-01 | 美商建南德克公司 | 用pd-1軸結合拮抗劑、抗代謝劑及鉑劑治療肺癌之方法 |
| MX2021001453A (es) | 2018-08-08 | 2021-04-12 | Genentech Inc | Uso de derivados de triptofano y l-metionina para una formulacion de proteinas. |
| JP7475336B2 (ja) | 2018-09-21 | 2024-04-26 | ジェネンテック， インコーポレイテッド | トリプルネガティブ乳癌のための診断方法 |
| MX2022015877A (es) | 2020-06-16 | 2023-01-24 | Genentech Inc | Metodos y composiciones para tratar cancer de mama triple negativo. |
| TW202517141A (zh) | 2023-07-13 | 2025-05-01 | 新加坡商蜂鳥生物科技私人有限公司 | 生產抗體的方法 |
| TW202509209A (zh) | 2023-07-13 | 2025-03-01 | 新加坡商蜂鳥生物科技私人有限公司 | 生產抗體的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) * | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6475787B1 (en) * | 1989-07-28 | 2002-11-05 | Wyeth | Method for producing monoclonal antibodies |
| EP0746609A4 (en) * | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
-
2000
- 2000-03-30 CA CA002368734A patent/CA2368734C/en not_active Expired - Lifetime
- 2000-03-30 EP EP00912975A patent/EP1167537B1/en not_active Expired - Lifetime
- 2000-03-30 AT AT00912975T patent/ATE402267T1/de not_active IP Right Cessation
- 2000-03-30 DE DE60039596T patent/DE60039596D1/de not_active Expired - Lifetime
- 2000-03-30 WO PCT/JP2000/002022 patent/WO2000058499A1/ja not_active Ceased
- 2000-03-30 AU AU34563/00A patent/AU754808B2/en not_active Expired
- 2000-03-30 DK DK00912975T patent/DK1167537T3/da active
-
2005
- 2005-09-28 US US11/238,983 patent/US8236530B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1167537B1 (en) | 2008-07-23 |
| US8236530B2 (en) | 2012-08-07 |
| CA2368734A1 (en) | 2000-10-05 |
| ATE402267T1 (de) | 2008-08-15 |
| US20060059575A1 (en) | 2006-03-16 |
| CA2368734C (en) | 2005-08-23 |
| EP1167537A4 (en) | 2005-05-04 |
| WO2000058499A1 (fr) | 2000-10-05 |
| DE60039596D1 (de) | 2008-09-04 |
| AU3456300A (en) | 2000-10-16 |
| EP1167537A1 (en) | 2002-01-02 |
| AU754808B2 (en) | 2002-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1167537T3 (da) | Fremgangsmåde til fremstilling af et monoklonalt antistof | |
| DK0610046T3 (da) | Ekspressionsvektorer kodende for bispecifikke fusionsproteiner og fremgangsmåder til fremstilling af biologisk aktive, bispecifikke fusionsproteiner i en pattedyrscelle | |
| NZ324076A (en) | A composition comprising an immunoglobulin having an affinity constant for binding to predetermined human antigen and transgenic non-human animals capable of producing heterologous antibodies | |
| DK1583830T3 (da) | Fremgangsmåde til fremstilling af rekombinante polyklonale proteiner | |
| DK0419858T3 (da) | Hunde-muse-heterohybridom og genfragment, som koder for den konstante region af hundeimmunglobuliner | |
| DE3278203D1 (en) | Monoclonal antibodies specific for the human transferrin receptor glycoprotein | |
| DK0380068T3 (da) | Ekspressionssystem til fremstilling af kimære monoklonale antistoffer | |
| DE59007589D1 (de) | Verfahren zur Herstellung hetero-bispezifischer Antikörper. | |
| DK0773228T3 (da) | Fremgangsmåde til fremstilling af monoklonale human-antistoffer og deres anvendelse | |
| DK0613944T3 (da) | Fremgangsmåder til regulering af immunresponset under anvendelse af CTLA4-bindende molekyler og IL4-bindende molekyler | |
| Shulman et al. | Mutations affecting the structure and function of immunoglobulin M | |
| NO2007014I1 (no) | Bevacizumab (rekombinant humanisert monoklonalt antistoff) | |
| NL300335I1 (nl) | Menselijke monoklonale antilichamen tegen epidermale groeifactorreceptor | |
| RU94045919A (ru) | Антитела, клетки, полипептид, днк векторы, способ получения полипептида, способ получения антитела, фармацевтическая композиция | |
| DK0763128T3 (da) | Fremgangsmåde til fremstilling af heterologe bispecifikke antistoffer | |
| DK1597280T3 (da) | Fremstilling af monoklone antistoffer ved EBV-transformation af B-celler | |
| DE60014124D1 (de) | Antikörper, die spezifisch für fullerene sind | |
| Groves et al. | Veterinary sources of nonrodent monoclonal antibodies: interspecific and intraspecific hybridomas | |
| DE3581288D1 (de) | Antileishmania monoklonale antikoerper, diese antikoerper ausscheidende hybridomas, von diesen antikoerpern erkannte leishmaniaantigene, verfahren zur herstellung und verwendung von diesen monoklonalen antikoerpern und antigenen. | |
| DK1092767T3 (da) | Serinproteasespecifikke monoklonale antistoffer og anvendelse deraf | |
| ATE217888T1 (de) | Monoklonale antikörper gegen leukozyten- spezifische g-protein-gekoppelte rezeptoren | |
| DE69635715D1 (de) | Monoklonaler antikoerper spezifisch fuer prostaglandin d synthetase | |
| AU2707992A (en) | Monoclonal antibodies to hepatitis c virus | |
| DK0733643T3 (da) | Membranprotein-polypeptid, som har den funktion at understøtte vækst af præ-B-celler og gen derfor | |
| DK326289D0 (da) | Fremgangsmaade til fremstilling af et protein ud fra gaersvampe under anvendelse af et inducerbart system, samt vektorer og transformerede stammer til brug ved fremgangsmaaden |